Results 181 to 190 of about 643,840 (294)

Autoantibodies to Joint‐Related Peptides Are Associated with Onset of Rheumatoid Arthritis in Presymptomatic Seronegative Individuals

Arthritis &Rheumatology, Accepted Article.
Objective To identify autoantibodies in presymptomatic individuals that associate with the onset of rheumatoid arthritis (RA), and to distinguish early RA from osteoarthritis (OA), particularly in individuals lacking classic RA serological markers. Methods We analyzed serum and plasma from three cohorts: pre‐symptomatic individuals who later developed ...
Outi Sareila, Linda Johansson, Anders Lundquist, Monica Leu Agelii, Lei Cheng, Yibo He, Erik Lönnblom, Maria Andersson, Jan Kihlberg, Anders Esberg, Inger Gjertsson, Rikard Holmdahl, Solbritt Rantapää‐Dahlqvist   +12 more
wiley   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Placebo response in RCT for antidepressant may not always be the 'villain' to fight: are KOR antagonists possibly affecting the intrinsic placebo response? [PDF]

Neuropsychopharmacology
Merlo Pich E.
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Addressing the impact of high placebo response in hot flash treatment trials. [PDF]

Am J Obstet Gynecol
Pei M, Gibson CJ, Grady D, Huang AJ.
europepmc   +1 more source

Cutoff criteria for the placebo response: a cluster and machine learning analysis of placebo analgesia. [PDF]

Sci Rep, 2021
Aslaksen PM.
europepmc   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

Decoding the impact of the placebo response in clinical trials for chronic cough. [PDF]

ERJ Open Res
Zhang M, Zhang B, Morice AH.
europepmc   +1 more source

Correction to: Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis. [PDF]

Schizophr Bull, 2023
europepmc   +1 more source

The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder. [PDF]

Br J Clin Pharmacol, 2022
Nasser A, Gomeni R, Wang Z, Hull JT, Busse GD, Melyan Z, Fava M, O'Neal W, Rubin J.   +8 more
europepmc   +1 more source